S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Closing prices for crude oil, gold and other commodities
Comprehensive Analysis of PayPal Stock
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Closing prices for crude oil, gold and other commodities
Comprehensive Analysis of PayPal Stock
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Closing prices for crude oil, gold and other commodities
Comprehensive Analysis of PayPal Stock
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Closing prices for crude oil, gold and other commodities
Comprehensive Analysis of PayPal Stock
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
NASDAQ:FREQ

Frequency Therapeutics (FREQ) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.28
$0.32
50-Day Range
$0.22
$14.98
52-Week Range
$0.18
$16.00
Volume
309,164 shs
Average Volume
822,537 shs
Market Capitalization
$10.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
FREQ stock logo

About Frequency Therapeutics Stock (NASDAQ:FREQ)

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

FREQ Stock News Headlines

Secret Bull Market Starts in This Unusual Sector
"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.
We tried it: Sound therapy, via app
Secret Bull Market Starts in This Unusual Sector
"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.
See More Headlines
Receive FREQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Frequency Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
4/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FREQ
Fax
N/A
Employees
46
Year Founded
N/A

Profitability

Net Income
$-81,580,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$14.07 million
Book Value
$1.96 per share

Miscellaneous

Free Float
30,385,000
Market Cap
$10.94 million
Optionable
Not Optionable
Beta
0.84
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. David L. Lucchino (Age 53)
    Co-Founder, President, CEO & Director
    Comp: $1.02M
  • Mr. Richard J. Mitrano (Age 52)
    Vice President of Finance & Operations
  • Mr. James P. Abely
    Associate General Counsel & Secretary
  • Dr. John L. LaMattina Ph.D. (Age 73)
    Senior Advisor & Member of PCA Regenerative Medicine Advisory Board

FREQ Stock Analysis - Frequently Asked Questions

Should I buy or sell Frequency Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Frequency Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" FREQ shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FREQ, but not buy additional shares or sell existing shares.
View FREQ analyst ratings
or view top-rated stocks.

How were Frequency Therapeutics' earnings last quarter?

Frequency Therapeutics, Inc. (NASDAQ:FREQ) issued its quarterly earnings data on Monday, November, 15th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.57) by $0.16.

What other stocks do shareholders of Frequency Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Frequency Therapeutics investors own include AbbVie (ABBV), Fulcrum Therapeutics (FULC), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Pfizer (PFE), Taiwan Semiconductor Manufacturing (TSM), Atreca (BCEL), Cidara Therapeutics (CDTX), Clovis Oncology (CLVS) and Chimerix (CMRX).

When did Frequency Therapeutics IPO?

Frequency Therapeutics (FREQ) raised $102 million in an initial public offering (IPO) on Thursday, October 3rd 2019. The company issued 6,700,000 shares at $14.50-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Mizuho Securities was co-manager.

This page (NASDAQ:FREQ) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners